Solasia Pharma K.K Management

Management criteria checks 2/4

Solasia Pharma K.K's CEO is Yoshihiro Arai, appointed in Feb 2013, has a tenure of 11.17 years. directly owns 0.63% of the company’s shares, worth €178.93K. The average tenure of the management team and the board of directors is 3.3 years and 6.6 years respectively.

Key information

Yoshihiro Arai

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	11.2yrs
CEO ownership	0.6%
Management average tenure	3.3yrs
Board average tenure	6.6yrs

Recent management updates

Recent updates

CEO

Yoshihiro Arai (63 yo)

11.2yrs

Tenure

Mr. Yoshihiro Arai has been the President and Representative Director at Solasia Pharma KK since February 2013 and serves as its Chief Executive Officer since July 2021. Mr. Arai served as Executive Vice P...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yoshihiro Arai	President	11.2yrs	no data	0.63% ¥ 178.9k
Toshio Miyashita	CFO, GM of Management Headquarters & Director	no data	no data	0.27% ¥ 77.1k
Yasumitsu Shimada	Accounting Manager	no data	no data	no data
Yasuaki Manabe	Head of Marketing Division	4.3yrs	no data	no data
Koji Shinozaki	Head of Business Development Department	no data	no data	no data
Fumiko Nagahama	Head of Product Development Division	no data	no data	no data
Hikaru Osawa	Head of Production Management Division	2.3yrs	no data	no data
Wataru Kobayashi	Head of Reliability Assurance Division	2.3yrs	no data	no data

3.3yrs

Average Tenure

Experienced Management: 9SO's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yoshihiro Arai	President	11.2yrs	no data	0.63% ¥ 178.9k
Toshio Miyashita	CFO, GM of Management Headquarters & Director	8.3yrs	no data	0.27% ¥ 77.1k
Yoshiyuki Yamakawa	Auditor	4.1yrs	no data	no data
Makoto Matsuo	External Corporate Auditor	no data	no data	no data
Stanley Lau	Independent Outside Director	no data	no data	no data
Norikazu Eiki	Independent Outside Director	7.9yrs	no data	no data
Susumu Araki	Statutory Auditor	5.3yrs	no data	no data
Jiro Mizukawa	Independent Outside Director	4.1yrs	no data	no data

6.6yrs

Average Tenure

70yo

Average Age

Experienced Board: 9SO's board of directors are considered experienced (6.6 years average tenure).

Solasia Pharma K.K Management

Management criteria checks 2/4

Key information

Recent management updates

Solasia Pharma K.K., Annual General Meeting, Mar 22, 2024

Insufficient new directors

Solasia Pharma K.K., Annual General Meeting, Mar 23, 2023

Solasia Pharma K.K., Annual General Meeting, Feb 24, 2022

Solasia Pharma K.K., Annual General Meeting, Mar 29, 2021

Recent updates

Full year 2023 earnings released: JP¥6.61 loss per share (vs JP¥16.77 loss in FY 2022)

New minor risk - Profitability

Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited

Forecast breakeven date pushed back to 2026

Full year 2023 earnings released: JP¥6.61 loss per share (vs JP¥16.77 loss in FY 2022)

Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited

Solasia Pharma K.K., Annual General Meeting, Mar 22, 2024

New minor risk - Shareholder dilution

New major risk - Financial position

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Solasia Pharma K.K. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: JP¥1.97 loss per share (vs JP¥4.95 loss in 3Q 2022)

Second quarter 2023 earnings released: JP¥1.17 loss per share (vs JP¥4.38 loss in 2Q 2022)

Second quarter 2023 earnings released: JP¥1.17 loss per share (vs JP¥4.38 loss in 2Q 2022)

First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥4.61 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: JP¥16.77 loss per share (vs JP¥19.04 loss in FY 2021)

Full year 2022 earnings released: JP¥16.77 loss per share (vs JP¥19.04 loss in FY 2021)

Solasia Pharma K.K., Annual General Meeting, Mar 23, 2023

Solasia Pharma K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023

Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. (TSE:4597) from ITOCHU Corporation (TSE:8001).

Third quarter 2022 earnings released: JP¥4.95 loss per share (vs JP¥5.46 loss in 3Q 2021)

Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Now 21% undervalued after recent price drop

Solasia Announces Summary of SP-04 PledOx Development Status

Solasia Announces Summary of SP-04 PledOx Development Status

Solasia Announces Launch of Darvias in Japan

Second quarter 2022 earnings released: JP¥4.38 loss per share (vs JP¥5.67 loss in 2Q 2021)

Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Solasia Pharma K.K. Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)

Solasia Pharma K.K. announced that it has received ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. announced that it has received ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

Solasia Pharma K.K. announced that it expects to receive ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. Announces an Organoarsenic Drug "Darvias® Injection 135Mg" (Sp-02, Hereinafter Darvias®) Has Been Approved for Relapsed or Refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare

First quarter 2022 earnings released: JP¥4.61 loss per share (vs JP¥5.22 loss in 1Q 2021)

Solasia Pharma K.K. announced that it has received ¥3.94289 billion in funding from Macquarie Group Limited

Solasia Pharma K.K. announced that it has received ¥3.94289 billion in funding from Macquarie Group Limited

Solasia Pharma K.K. to Report Q3, 2022 Results on Nov 11, 2022

Solasia Pharma K.K. announced that it expects to receive ¥3.44289 billion in funding from Macquarie Group Limited

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Solasia Pharma K.K., Annual General Meeting, Feb 24, 2022

Third quarter 2021 earnings released: JP¥5.46 loss per share (vs JP¥5.71 loss in 3Q 2020)

Second quarter 2021 earnings released: JP¥5.67 loss per share (vs JP¥6.36 loss in 2Q 2020)

Solasia Pharma K.K. Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan

First quarter 2021 earnings released: JP¥5.22 loss per share (vs JP¥4.54 loss in 1Q 2020)

Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019)

Solasia Pharma K.K. to Report Q1, 2021 Results on May 12, 2021

New 90-day high: €1.24

Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019)

Solasia Pharma K.K., Annual General Meeting, Mar 29, 2021

Solasia Pharma K.K. to Report Fiscal Year 2020 Results on Feb 16, 2021

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Year Ending December 31, 2020

New 90-day low: €1.06

Third quarter 2020 earnings released: JP¥5.71 loss per share

New 90-day low: €1.15

New 90-day low: €1.30

New 90-day low - €1.36

Solasia Pharma K.K. announced that it expects to receive ¥13.44 million in funding from Macquarie Group Limited

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age